Pegaptanib sodium shows promise in treatment of CRVO

Article

Treatment of macular edema secondary to central retinal vein occlusion (CRVO) with pegaptanib sodium (Macugen, OSI/Eyetech, Pfizer Ophthalmics) was associated with improved visual acuity in a comparison with patients receiving sham injections. This finding suggests that pegaptanib, which inhibits vascular endothelial growth factor (VEGF), may provide functional benefits to patients with CRVO, said John A. Wells III, MD, a private practitioner at the Palmetto Retina Center, Columbia, SC.

Treatment of macular edema secondary to central retinal vein occlusion (CRVO) with pegaptanib sodium (Macugen, OSI/Eyetech, Pfizer Ophthalmics) was associated with improved visual acuity in a comparison with patients receiving sham injections. This finding suggests that pegaptanib, which inhibits vascular endothelial growth factor (VEGF), may provide functional benefits to patients with CRVO, said John A. Wells III, MD, a private practitioner at the Palmetto Retina Center, Columbia, SC.

Dr. Wells presented results of the phase II study on behalf of the Pegaptanib in CRVO Study, a trial performed to assess the safety and efficacy of the drug in treating macular edema secondary to CRVO. Since pegaptanib slows vision loss in age-related macular degeneration and reduces diabetic macular edema, investigators wanted to study the drug's effect in CRVO, a condition involving overexpression of VEGF. However, because of damage to the retinal vasculature and neurosensory retina present in CRVO, selective inhibition of (VEGF) might be more beneficial than nonselective inhibition, Dr. Wells said.

The trial included 98 subjects enrolled at 36 centers internationally who were randomized to 0.3 mg (n = 33) of pegaptanib, 1 mg (n = 33), or sham (n = 32). They received intravitreous injections every six weeks for 24 weeks; follow-up continued through 52 weeks. Rescue therapy was permitted after week 30; eight patients in the 0.3-mg group, seven in the 1-mg group, and two in the sham group received this treatment.

Baseline vision was about 48 letters in all three groups, visual acuity was about 20/100, and the mean central retinal thickness was also similar, Dr. Wells said.

An early and sustained treatment effect was shown in the active treatment groups. At week 30, there was almost a 10-letter gain in the 1-mg arm, a seven-letter gain in the 0.3-mg group, and a three-letter loss in the sham group.

The primary endpoint of the trial was the proportion of patients who gained 15 letters or more (3 lines) at week 30.

"While there was a trend favoring the Macugen eyes, it failed to meet that endpoint," Dr. Wells said. The proportion of patients gaining 15 letters or more was 36% in the 0.3-mg group and 39% in the 1-mg group, compared to 28% in the controls.

At week 52, the mean change in baseline was a gain of 7.5 letters for the 0.3-mg group and 6.3 letters in the 1-mg group compared with a loss of 2.4 letters in the sham group. The difference was not statistically significant. Fewer subjects treated with 0.3-mg of pegaptanib lost ≥15 letters than those in the sham group at 52 weeks (6% versus 31%, p p p

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.